Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial Results
March 02 2017 - 4:05PM
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated
to significantly improving the health and well-being of patients
affected by metabolic diseases including type 2 diabetes and
obesity, announced today that it will host a conference call on
Thursday, March 9, 2017 at 4:30 p.m. ET to discuss its financial
results for the fourth quarter and full year ended December 31,
2016.
Participants may access the call by dialing
(844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and
referencing conference ID number 77476849. The call will also be
webcast live on the Company's website at
http://ir.zafgen.com/events.cfm. A replay of this conference call
will be available beginning at 7:30 p.m. ET on March 9, 2017
through March 16, 2017 by dialing (855) 859-2056 in the U.S. or
(404) 537-3406 outside the U.S. To access the replay please provide
Conference ID number 77476849.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical
company dedicated to significantly improving the health and
well-being of patients affected by metabolic diseases including
type 2 diabetes and obesity. Zafgen is focused on developing novel
therapeutics that treat the underlying biological mechanisms of
metabolic diseases through the MetAP2 pathway. Zafgen has pioneered
the study of MetAP2 inhibitors in both common and rare forms of
obesity. Zafgen's lead product candidate is ZGN-1061, which is a
novel, first-in-class, twice-weekly subcutaneous injection. Zafgen
aspires to improve the lives of patients through targeted
treatments and has assembled a team accomplished in bringing
therapies to patients affected by metabolic diseases.
Investor Relations Contact:
Argot Partners
Investor Relations
Laura Perry or Glenn Garmont
212-600-1902
laura@argotpartners.com
glenn@argotpartners.com
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Sep 2023 to Sep 2024